Table 2.

Significant interactions in UCP and replication results from the HVH study.

		UCP							HVH

Gene	SNP	G	#	HWE	p	q	OR^*(95% CI)	OR^**(95% CI)	RSQR	#	HWE	p	OR^* (95% CI)	OR^** (95% CI)

SCARB1	rs4765615	AA	452				0.80 (0.53–1.20)	0.63 (0.41–0.97)	0.23
		AG	837	0.54	0.001	0.19	0.33 (0.24–0.46)	0.29 (0.21–0.41)
		GG	411				0.38 (0.24–0.61)	0.31 (0.19–0.51)
		--	185
PCSK9	rs10888896	CC	119				1.44 (0.65–3.18)	1.38 (0.60–3.16)	0.18
		CG	658	0.12	0.003	0.24	0.37 (0.26–0.54)	0.32 (0.22–0.47)
		GG	1105				0.40 (0.31–0.53)	0.34 (0.25–0.45)
		--	3
ABCG5	rs4245786	AA	1099				0.56 (0.43–0.73)	0.46 (0.35–0.61)	0.08
		AG	692	0.23	0.016	0.57	0.26 (0.18–0.37)	0.24 (0.16–0.34)
		GG	93				0.49 (0.19–1.24)	0.38 (0.13–1.12)
		--	1
ABCG5	rs1864815	AA	834				0.60 (0.44–0.81)	0.48 (0.35–0.67)	0.68	1071			0.96 (0.70–1.33)	0.80 (0.57–1.13)
		AT	835	0.61	0.022	0.57	0.29 (0.21–0.40)	0.25 (0.18–0.36)		1104	0.646	0.82	0.99 (0.72–1.36)	0.83 (0.60–1.17)
		TT	198				0.38 (0.20–0.74)	0.42 (0.21–0.84)		271			1.23 (0.62–2.44)	0.98 (0.47–2.04)
		--	18							0
LIPC	rs16940379	GG	986				0.47 (0.35–0.62)	0.38 (0.28–0.51)	0.82	168			0.88 (0.66–1.18)	0.69 (0.51–0.95)
		CG	749	0.68	0.031	0.57	0.32 (0.23–0.45)	0.28 (0.20–0.40)		939	0.637	0.45	1.15 (0.81–1.63)	1.02 (0.70–1.46)
		CC	149				0.83 (0.38–1.82)	0.81 (0.36–1.79)		1339			1.38 (0.54–3.53)	1.43 (0.52–3.93)
		--	1							0
ABCA1	rs4149264	CC	1192				0.52 (0.40–0.68)	0.44 (0.34–0.58)
		CG	607	0.67	0.034	0.57	0.27 (0.19–0.40)	0.23 (0.15–0.34)	0.35
		GG	82				0.54 (0.19–1.51)	0.50 (0.16–1.58)
		--	4
PPARG	rs2972164	GG	585				0.42 (0.26–0.65)	0.35 (0.22–0.57)	1.00	507			1.06 (0.73–1.54)	0.96 (0.64–1.43)
		AG	897	0.14	0.034	0.57	0.33 (0.24–0.45)	0.28 (0.20–0.39)		1176	0.48	0.89	1.00 (0.73–1.37)	0.79 (0.57–1.11)
		AA	395				0.60 (0.42–0.85)	0.49 (0.34–0.72)		763			1.02 (0.64–1.64)	0.84 (0.50–1.39)
		--	8							0
PCSK9	rs505151	AA	1632				0.42 (0.33–0.52)	0.36 (0.28–0.45)	NI^†	788			0.69 (0.46–1.04)	0.61 (0.39–0.94)
		G	158	0.23	0.038	0.57	0.91 (0.46–1.79)	0.63 (0.30–1.32)		76	0.621	0.56	1.47 (0.38–5.71)	1.05 (0.18–6.26)
		--	95							1
LRP1	rs715948	GG	908				0.17 (0.08–0.37)	0.17 (0.08–0.37)	1.05	271			0.95 (0.70–1.29)	0.79 (0.57–1.09)
		AG	794	0.7	0.04	0.57	0.49 (0.36–0.67)	0.44 (0.31–0.60)		1011	0.058	0.93	1.06 (0.76–1.47)	0.90 (0.63–1.28)
		AA	181				0.45 (0.33–0.60)	0.36 (0.26–0.49)		1164			1.12 (0.54–2.31)	0.86 (0.39–1.86)
		--	2							0
SOAT1	rs2493121	AA	217				0.20 (0.11–0.39)	0.19 (0.10–0.38)
		AT	832	0.75	0.047	0.57	0.49 (0.36–0.68)	0.43 (0.31–0.60)	0.51
		TT	824				0.44 (0.32–0.61)	0.36 (0.25–0.50)
		--	12

For each gene and SNP, the number of subjects for each genotype are given, together with the HWE. The SI was used to test for the interaction between the genotype and statin treatment. The p value for each interaction denotes whether there is an overall difference in the effectiveness of statins between the three genotype groups (with two degrees of freedom). The q value gives an estimate of the proportion of false discoveries among the statistically significant results. For each genotype stratum, the OR reflects the effectiveness of statins within the specific genotype group. The RSQR is a measure for the quality of an imputed SNP in the HVH (cut-off=0.6).

-- = missing genotype

OR = odds ratio

SI = synergy index

= adjusted for age, sex, region, index date

^**

= adjusted for age, sex, region, index date, use of calcium channel blockers, and ischemic heart disease

G = genotype

# = number of participants

HWE = Hardy-Weinberg equilibrium

lower = lower limit of the 95% confidence interval

upper = upper limit of the 95% confidence interval

p = p-value for the interaction

q = q-value for the interaction

NI = not imputed

RSQR = the average of the observed by expected variance ratio

^†

= HVH study data only available from the Illumina GoldenGate pan